/
Oncology
Malignancy
53
Pipeline Programs↗
43
Active Trials↗
31
Companies Involved↗
Malignancy is a moderately active landscape with 53 programs across 31 companies. The most active players are Takeda.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical32
Phase 17
Anti-Human Thymoglobulin
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
CD45RA-Depleted DLI
St. Jude Children's Research Hospital
GTB-360
Masonic Cancer Center, University of Minnesota
CTA101
The First Affiliated Hospital with Nanjing Medical University
Hrs-1635
Chengdu Suncadia Medicine Co., Ltd.
Phase 214
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
76%
Small molecule
35 of 46 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 46 classified programs, each share of the total. Modality classified for 92% of 53 pipeline programs.
Analysis
Trial Status
109
clinical trials
Completed39 · 36%
Recruiting32 · 29%
Unknown status14 · 13%
Terminated9 · 8%
Not yet recruiting6 · 6%
Active, not recruiting5 · 5%
Other4 · 4%
Clinical Trials
Trial Activity
109 trials
Page 1 of 8
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)